Tremelimumab

Therapeutic indications

Tremelimumab is indicated for:

Hepatocellular carcinoma

Population group: only adults (18 years old or older)

Tremelimumab in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

300 mg once in combination with 1,500 mg durvalumab at Cycle 1/Day 1 and thereafter durvalumab monotherapy every 4 weeks

Metastatic non-small cell lung cancer, with no EGFR or ALK positive mutations

Population group: only adults (18 years old or older)

Non-small cell lung cancer, negative for epidermal growth factor receptor expression and additionally Anaplastic lymphoma kinase negative non-small cell lung cancer

For this indication, competent medicine agencies globally authorize below treatments (click for details):

75 mg every 3 weeks for 4 cycles during platinum chemotherapy and a fifth doseof 75 mg at week 16 at post-platinum chemotherapy

Contraindications

Tremelimumab is contraindicated in the following cases:

Pregnancy

Lactation

Systemic corticosteroids or immunosuppressants before starting tremelimumab

at least one of

Corticosteroid drugs
Immunosuppressants

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.